Kennedy Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Kennedy Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-605,314	Closed	-$8.95M	–	778
2017 Q1	$8.95M	Sell	605,314 -484,727	-44%	-$7.85M	0.16%	221
2016 Q4	$17.6M	Buy	1,090,041 +331,036	+44%	+$6M	0.31%	79
2016 Q3	$13.8M	Buy	759,005 +32,536	+4%	+$636K	0.26%	105
2016 Q2	$12M	Buy	726,469 +258,065	+55%	+$4.18M	0.24%	123
2016 Q1	$7.76M	Sell	468,404 -98,576	-17%	-$1.72M	0.16%	221
2015 Q4	$12.3M	Sell	566,980 -31,489	-5%	-$613K	0.25%	110
2015 Q3	$11.9M	Sell	598,469 -159,779	-21%	-$5.05M	0.24%	108
2015 Q2	$26.3M	Sell	758,248 -683,701	-47%	-$20.9M	0.47%	30
2015 Q1	$37.4M	Buy	+1,441,949	New	+$26.4M	0.66%	2
2013 Q4	–	Sell	-360,688	Closed	-$1.21M	–	801
2013 Q3	$1.21M	Sell	360,688 -350,014	-49%	-$923K	0.02%	617
2013 Q2	$1.75M	Buy	+710,702	New	+$1.71M	0.04%	556

Other funds holding HZNP

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Kennedy Capital Management's HZNP Position: Q2 2017 in Review

Kennedy Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 605,314 shares — an estimated $8.95M sold.

Kennedy Capital Management first reported a position in HZNP in Q2 2013 and held it in 11 quarters. The position peaked at $37.4M in Q1 2015. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

Kennedy Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Kennedy Capital Management sold 605,314 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $8.95M.
Kennedy Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 11 quarters.
Kennedy Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $37.4M in Q1 2015.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on Kennedy Capital Management's 13F filing for Q2 2017, filed 10 Aug 2017.